Group 1 - The implementation of the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) has added 8 new drugs focused on breast cancer, with 2 drugs expanding their indications [1] - Breast cancer is the most common malignant tumor among women globally and the second leading cause of cancer-related deaths among women in China, with over 350,000 new cases and approximately 75,000 deaths reported in 2022 [1] - The most common molecular subtype of breast cancer is HR+/HER2-, accounting for about 70% of all breast cancer patients [1] Group 2 - For HR+/HER2- advanced breast cancer patients, the standard first-line treatment is endocrine therapy combined with CDK 4/6 inhibitors, but there is currently no standard treatment for those whose condition progresses after this therapy [2] - Recent updates to the medical insurance catalog have included innovative drugs in the breast cancer field, significantly reducing the treatment burden for patients, including targeted drugs for the PAM pathway that fill clinical treatment gaps [2] - The development of personalized precision treatment plans through genetic testing is becoming increasingly important, as it helps predict disease progression and improve treatment efficiency [3] Group 3 - The importance of genetic testing in precision medicine is highlighted, although it can be costly and may face challenges in clinical implementation [3] - There is an expectation that common genetic testing projects will eventually be included in medical insurance in China, similar to practices in Europe and the United States, to promote better medical development [3]